Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP Adherence to iron chelation therapy (%, SD) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 4 studies · 369 participants | Low |
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP Incidence of SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | RR 0.15 [0.01, 2.81] | 1 study · 213 participants | Low |
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP All‐cause mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | 0.77 [0.17, 3.42] | 2 studies · 237 participants | Very low |
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP QoL Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO Adherence to iron chelation therapy (%, SD) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 5 studies · 281 participants | Low |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO Incidence of SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 4 studies · 180 participants | Low |
Summary of findings: Comparison 1 ‐ deferiprone (DFP) vs deferoxamine (DFO) All‐cause mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | RR 0.47 [0.18, 1.21] | 3 studies · 376 participants | Very low |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO All‐cause mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO QoL Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) Adherence to iron chelation therapy rates (n, N) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | RR 0.84 [0.72, 0.99] | 1 study · 96 participants | Low |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) Incidence of SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | 1 [0.06, 16.22] | 1 study · 96 participants | Very low |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) All‐cause mortality ‐ at 1 year ‐ trial end Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | RD 0 | 1 study · 96 participants | Very low |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) QoL Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 1 study · 96 participants | Ungraded |
Summary of findings: Comparison 8 ‐ medication management vs standard care Adherence to iron chelation Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 1 ‐ deferiprone (DFP) vs deferoxamine (DFO) Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care Mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care QoL PedsQLTM total score Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 1 study · 48 participants | Very low |
Summary of findings: Comparison 1 ‐ deferiprone (DFP) vs deferoxamine (DFO) QoL ( Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 1 study · 1 participants | Very low |
Summary of findings: Comparison 2 ‐ deferasirox (DFX) vs deferiprone (DFO) Adherence to iron chelation therapy (%, SD) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 3 studies · 452 participants | Very low |
Summary of findings: Comparison 2 ‐ deferasirox (DFX) vs deferiprone (DFO) SAEs Thalassaemia‐related SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | RR 0.95 [0.41, 2.17] | 2 studies · 247 participants | Very low |
Summary of findings: Comparison 2 ‐ deferasirox (DFX) vs deferiprone (DFO) SAEs SCD‐related SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | 1 study · 195 participants | Very low |
Summary of findings: Comparison 2 ‐ deferasirox (DFX) vs deferiprone (DFO) All‐cause mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | 0.96 [0.06, 15.42] | 2 studies · 240 participants | Very low |
Hydroxyurea vs placebo Reduction or prevention of kidney disease progression · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | 1 study · 142 participants | Very low |
Angiotensin‐converting enzyme inhibitors vs vitamin C Serious adverse events · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Mortality due to any cause · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Quality of life · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo Serious adverse events · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | RR 0.39 [0.13, 1.16] | 1 study · 193 participants | Low |
Hydroxyurea vs placebo All‐cause mortality · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | 1 study · 193 participants | Low |
Hydroxyurea vs placebo Quality of life · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo Reduction or prevention of kidney disease progression · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Angiotensin‐converting enzyme inhibitors vs placebo Serious adverse events · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo All‐cause mortality · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo Quality of life · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Reduction or prevention of kidney disease progression · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | 1 study · 170 participants | Very low |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Change in class of malocclusion · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in DMFT index · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in severity of gingivitis (measured by BoP) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | 1 study · 29 participants | Very low |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: reduction in severity of periodontitis (measured by reduction in clinical attachment loss) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: oral infections (measured by reduction in or resolution of lesions such as periapical cysts, abscesses, or space infections) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Resolution or reduction in severity of any other dental complication: systemic infections (measured by number of episodes after treatment for dental complications under antibiotic prophylaxis) · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone Any other adverse effects related to treatment · people with thalassaemia Treatment of dental and orthodontic complications in thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa vs placebo Change from baseline in 6MWT (metres) · 90 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | 1 study · 90 participants | Moderate |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Infusion reactions · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Need for respiratory support · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo Use of a walking aid / wheelchair · 13 people with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane | no estimate extracted | NR | No studies |